Home Home Benjamin J. Frisch, Ph.D.

Benjamin J. Frisch, Ph.D.

Contact

Office (585) 276-7148

About Me
Research
Publications

About Me

Faculty Appointments

Assistant Professor - Department of Pathology and Laboratory Medicine (SMD)

Assistant Professor - Department of Biomedical Engineering (SMD) - Joint

Research

Since 2007 my research career has had a translational focus, with a particular interest in microenvironmental support for the hematopoietic stem cell (HSC). Discovery of mechanisms of support for HSCs during both homeostatic and stressed hematopoiesis has evolved to the identification of novel therapeutic targets in malignant hematopoiesis, such as acute myeloid leukemia. My current research is focused on alterations of the bone marrow microenvironment induced by myeloid malignancies. This research has led to the identification of the chemokine CCL3 as a potential target for the treatment of acute myeloid leukemia. My future interests are in further characterization of the interactions between malignant hematopoiesis and the bone marrow microenvironment, with the ultimate goal of translation of novel therapeutic targets to clinical use.

Patents

Compositions and Methods for Controlled Localized Delivery of Bone Forming Therapeutic Agents

Issue date: February 05, 2019

Patent #: 10,195,284

Country: United States

Inventors: Danielle SW Benoit, Benjamin J Frisch, Maureen Newman, J. Edward Puzas, Tzong-Jen Sheu

Publications

Journal Articles

The hematopoietic stem cell niche: What's so special about bone?

Frisch BJ

Bone.. 2019 February 119 :8-12. Epub 05/17/2018.

EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription.

Ayoub E, Wilson MP, McGrath KE, Li AJ, Frisch BJ, Palis J, Calvi LM, Zhang Y, Perkins AS

Nature communications.. 2018 October 129 (1):4239. Epub 10/12/2018.

The Chemokine CCL3 Regulates Myeloid Differentiation and Hematopoietic Stem Cell Numbers.

Staversky RJ, Byun DK, Georger MA, Zaffuto BJ, Goodman A, Becker MW, Calvi LM, Frisch BJ

Scientific reports.. 2018 October 28 (1):14691. Epub 10/02/2018.

The Notch Ligand Jagged1 Regulates the Osteoblastic Lineage by Maintaining the Osteoprogenitor Pool.

Lawal RA, Zhou X, Batey K, Hoffman CM, Georger MA, Radtke F, Hilton MJ, Xing L, Frisch BJ, Calvi LM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.. 2017 June 32 (6):1320-1331. Epub 03/09/2017.

Prostaglandin E2 increases hematopoietic stem cell survival and accelerates hematopoietic recovery after radiation injury.

Porter RL, Georger M, Bromberg O, McGrath KE, Frisch BJ, Becker MW, Calvi LM

Stem cells.. 2013 February 31 (2):372-83. Epub 1900 01 01.

Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells.

Bromberg O, Frisch BJ, Weber JM, Porter RL, Civitelli R, Calvi LM

Blood.. 2012 July 12120 (2):303-13. Epub 05/17/2012.

Osteoblastic expansion induced by parathyroid hormone receptor signaling in murine osteocytes is not sufficient to increase hematopoietic stem cells.

Calvi LM, Bromberg O, Rhee Y, Weber JM, Smith JN, Basil M, Frisch BJ, Bellido T

Blood.. 2012 March 15119 (11):2489-99. Epub 01/18/2012.

Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM

Blood.. 2012 January 12119 (2):540-50. Epub 09/28/2011.